Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services, reviews USP 797revisions and impacts on compounding pharmacies in the fourth of a four-part series.

Our four-part series continues with Part 2, USP 795 revisions and impacts on compounding pharmacies.

Matt Martin points out the most significant change in the newly proposed version of USP Chapter 797 as well as the cascading effects it has on the guidelines. He also explains the process for the proposed version to become official and what compounding pharmacies and other stakeholders should do about it now.

Thank you to all of our readers and subscribers for supporting the PCCA blog, your support is what makes it the best compounding pharmacy blog online! We’re grateful to be able to produce content that professionals in the pharmacy compounding industry find valuable. With that said, come check out the top five, most valuable PCCA Blog Posts of 2019 that you might have missed!

PCCA's Director of Formulation Development Melissa Merrell Rhoads, PharmD, provides part two in a set of posts detailing the upcoming changes to our formulas based upon the new USP guidelines. This particular section focuses on USP <797>.

Want some clarity on USP <797> and USP <800> updates? Our August updates to PCCA Play are designed to do just that with a free presentation from PCCA Education and Training Manager Jerra Banwarth, RPh, FIACP and Eagle President Ross Caputo, PhD. In another video, subscribers to PCCA Play can watch Eagle Vice President of Operations Megan Jeffrey Liotta, MS, discuss USP <797> regulation updates.